Table 2.
Pathoanatomical outcomes
| Final pTNM | NAC | No NAC | All | ||
|---|---|---|---|---|---|
| CR—complete response | SD—stable disease | PD—progressive disease | |||
| pT0N0M0 | 36 | 0 | 0 | 6 | 42 |
| pTisN0M0 | 0 | 5 | 0 | 0 | 5 |
| pTaN0M0 | 0 | 2 | 0 | 0 | 2 |
| pT1N0M0 | 0 | 5 | 0 | 1 | 6 |
| pT2N0M0 | 0 | 11 | 0 | 4 | 15 |
| pT3N0M0 | 0 | 10 | 0 | 10 | 20 |
| pT4aN0M0 | 0 | 2 | 0 | 1 | 3 |
| pT0N+ | 0 | 0 | 1 | 0 | 1 |
| pTisN+ | 0 | 0 | 1 | 0 | 1 |
| pT2N+ | 0 | 0 | 4 | 0 | 4 |
| pT3N+ | 0 | 0 | 5 | 7 | 12 |
| pT4aN+ | 0 | 0 | 1 | 2 | 3 |
| pT4bN+ | 0 | 0 | 0 | 1 | 1 |
| Any M+ | 0 | 0 | 0 | 1 | 1 |
Final pTNM-stages post-cystectomy for all included patients, stratified by subgroups. In the NAC-treated cohort; Complete Response (CR) was found in 43.4% (36/83), Stable Disease in 42.2% (35/83) and Progressive Disease in 14.4% (12/83) of the patients